The European Commission has granted marketing authorisation for Leqembi (lecanemab), making it the first therapy in the EU to slow the progression of early Alzheimer’s disease.

Real-world data from the University of Catania, Italy, suggest that Pepaxti, a treatment for relapsed, refractory multiple myeloma (RRMM), is effective and well tolerated in heavily pretreated ...

New data from Janssen-Cilag International NV suggest that subcutaneous DARZALEX (daratumumab) quadruplet therapy could offer ...

New UK clinical trials regulations have been signed into law, with a 12-month rollout starting 11 April. The reforms mark the ...

Birmingham researchers have received £230k from Cancer Research Horizons to develop a prototype test for monitoring people ...

A systematic literature review identified 362 records from 67 studies across 10 countries. Results showed romosozumab significantly improved bone mineral density at 12 months in lumbar spine, total ...

Johnson & Johnson’s Balversa was found to extend the lives of urothelial cancer patients with a genetic alteration ...

SkyCell has partnered with Microsoft to launch SkyMind, an artificial intelligence (AI)-powered solution designed to enhance ...

The MHRA has approved trofolastat to identify how far high-risk prostate cancer has spread before treatment, to detect ...

The NHS has started delivering its spring COVID-19 vaccine booster to vulnerable individuals across England, with over half a ...

Elekta has announced a partnership with Azra AI to improve cancer registry workflows using AI-powered automation. Combining ...

The European Commission (EC) has approved ustekinumab for the treatment of moderately to severely active Crohn’s disease in ...